PAD Profile : Metolazone - Heart failure

PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Metolazone - Heart failure

PAD Profile : Metolazone - Heart failure

Keywords :

congestive heart failure, oedema

Brand Names Include :

Xaqua

Traffic Light Status

Status 1 of 1.

Status :

Blue

Important

Formulations :

Tablets

Important Information :

Initiation by specialist. The licensed (Xaqua) and unlicensed (Zaroxolyn) tablets have different bioavailabilities. These products are not interchangable=Prescribe by Brand

Trust Alignment :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

BNF NICE SPC

Comments :

No comments returned.

Documents :

Guidelines

The following guidelines are available for this indication.

Guidelines : Heart failure

Other Drugs

Other Indications

Additional Documents

Type

Document

Review Date

Webpage

Differences-between-metolazone-preparations-and-safety-considerations

Committee Recommendations

Date

Committee Name

Narrative

14 September 2022

Surrey Heartlands Medicines Safety Committee (MSC)

When initiating patients on metolazone the licensed, branded Xaqua preparation should be prescribed.

Any switch between products should take into account the difference in bioavailability between Xaqua and other available unlicensed products.

Switching from the unlicensed (imported) product to Xaqua may require a reduction in dose by half, or for the same dose to be used but adjust the frequency from daily to alternate days.

The tablets have a single score-line and can be divided into equal halves.

Update March 2023:

Refer any patients who are taking unlicensed metolazone and have not been reviewed to the prescribing specialist for review and consideration for switching to the licensed product Xaqua

Associated BNF Codes

02. Cardiovascular System

02.02.01. Thiazides and related diuretics